甲磺酸齐拉西酮注射液治疗精神分裂症急性激越症状的临床评价

Clinical Evaluation on Treatment of Acute-agitation in Schizophrenia with Zipraside Injection

目的评价甲磺酸齐拉西酮注射液对精神分裂症急性激越症状的临床疗效及不良反应。方法选择住院患者60例,随机分配至治疗组(30例,予甲磺酸齐拉西酮注射液)与对照组(30例,予氟哌啶醇注射液),疗程3d。用精神分裂症阳性与阴性症状评定量表(PANSS)减分率、临床疗效总评量表(CGl)评定疗效,治疗结束时用副反应量表(TESS)评定安全性。结果疗程结束时PANSS减分率治疗组为(67.18±25.29)%,对照组为(66.94±23.89)%,临床好转率治疗组为70.00%,对照组为63.33%,组间疗效均无显著性差异;不良反应发生率治疗组为40.00%,对照组为43.33%,组间无显著性差异(P>0.05),但对照组的锥体外系反应发生率(肌强直、震颤、静坐不能及扭转性痉挛)明显高于治疗组(P<0.05)。结论甲磺酸齐拉西酮注射液能有效治疗精神分裂症的急性激越症状,疗效与氟哌啶醇注射液相当,且锥体外系反应明显少于后者。

Objective To assess the clinical effectiveness and the side effects of zipraside injection on the acute-agitation symptom in schizophrenia. Methods 60 inpatients met with the criterion of schizophrenia, were arranged randomly, 30 cases for the treatment group and 30 cases for the control group. To evaluate the reduced rate with the positive and negative system scale （PANSS-EC）, the curative effect with CGI- IS and the safety with the treatment emergent symptom scale （TESS） after the end of the treatment. Results There was no remarkable difference （P 〉0.05） among the reduced rate of PANSS-EC in the treatment group[（67.18 ±25.29）%] and the control group[（66. 94 ± 23.89）% ].The clinical efficiency rate was 70.00% in the treatment group and 63.33% in the control group. The rate of side effects was 40. 00% in the treatment group and 43.33% in the control group respectively. The extrapyramidal symptoms （muscle-bound, thrill, hyperkinesias and tic） in the control group were much higher in than those in the treatment group （P〈0. 05）. Conclusion Zipraside injection has remarkable clinical effect on the acute-agitation in schizophrenia, and corresponds with haloperidol injection. But the extrapyramidal symptoms of zipraside injection are less than those of haloperidol injection.